Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will hold a conference call on May 9, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a corporate update. The company is known for its KORSUVA™ injection, the sole FDA-approved treatment for moderate-to-severe pruritus linked to chronic kidney disease in adults undergoing hemodialysis. Cara is also developing an oral version of difelikefalin and has initiated Phase 3 programs targeting pruritus in patients with chronic kidney disease and atopic dermatitis.

Positive

• KORSUVA™ is the first FDA-approved treatment for pruritus associated with chronic kidney disease.
• Phase 3 programs initiated for non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.
• Ongoing Phase 2 trials for Oral KORSUVA in primary biliary cholangitis and notalgia paresthetica.

Negative

• None.

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 9296276. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

When will Cara Therapeutics report its first quarter 2022 financial results?

Cara Therapeutics will report its first quarter 2022 financial results on May 9, 2022.

What is KORSUVA™ by Cara Therapeutics?

KORSUVA™ (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

What upcoming clinical trials is Cara Therapeutics conducting?

Cara Therapeutics is conducting Phase 3 trials for pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.

How can I access the Cara Therapeutics conference call?

The conference call can be accessed by dialing (855) 445-2816 for domestic calls or (484) 756-4300 for international calls, with conference ID 9296276.